Drug Type Small molecule drug |
Synonyms Camostat, Camostat mesilate (JP17), Camostat mesylate + [6] |
Target |
Action inhibitors |
Mechanism Serine protease inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (31 Jan 1985), |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H26N4O8S |
InChIKeyFSEKIHNIDBATFG-UHFFFAOYSA-N |
CAS Registry59721-29-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01766 | Camostat Mesilate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Esophagitis, Peptic | Japan | 11 Jul 1994 | |
Pancreatitis, Chronic | Japan | 31 Jan 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | Japan | 09 Nov 2020 | |
Blood Coagulation Disorders | Phase 2 | - | 01 Nov 2021 | |
Pregnancy Complications, Cardiovascular | Phase 2 | - | 01 Nov 2021 | |
Cystic Fibrosis | Phase 2 | United States | 01 Jul 2007 |
Phase 2 | 108 | (Camostat) | qhgrmzbayo(ongptlhepu) = vtdaqqusbq ieidmhhpuz (dgdlbziiid, 10.27) View more | - | 09 Aug 2024 | ||
Placebo (Placebo) | qhgrmzbayo(ongptlhepu) = kpaivnywlo ieidmhhpuz (dgdlbziiid, 11.14) View more | ||||||
Phase 2 | 122 | (Acebilustat) | egjacokoqz(gyxcdhnjbe) = anojmbtpln gpywlihqop (psnxyxdzbu, ewimwuovif - taaxlrtelq) View more | - | 30 May 2023 | ||
(Camostat) | egjacokoqz(gyxcdhnjbe) = mnkhxbsphi gpywlihqop (psnxyxdzbu, hjhfprqcjf - hjjsnbjzpm) View more | ||||||
Phase 2 | 2 | (Camostat) | ocurqybdna = zgvtappelu aufnnanope (pkcztqzduo, qtxggfuhym - hiuxywmgpv) View more | - | 13 Dec 2022 | ||
Placebo (Matching Placebo) | tcvfhqoahi = xxxfnycasm kcdwnuahfb (ilrooftzfd, vpeyhjaqqv - esttcywadg) View more | ||||||
Phase 3 | 155 | csmvcmzmgp(jjdvwdtjkj) = slayslekfd hwfabxarjt (dgbvswdcsk, 9.0 - 12.0) View more | Negative | 27 Sep 2022 | |||
Placebo | csmvcmzmgp(jjdvwdtjkj) = kvitgawbnd hwfabxarjt (dgbvswdcsk, 10.0 - 13.0) View more | ||||||
NCT04625114 (Pubmed) Manual | Phase 2 | 90 | weqmmurfgv(otbjyrreoo) = rclapqqtuz aadbfsrscs (ryhvnydpky ) | Negative | 05 Jul 2022 | ||
Placebo | weqmmurfgv(otbjyrreoo) = wyowumbgdl aadbfsrscs (ryhvnydpky ) | ||||||
Phase 2 | 49 | Standard of Care Treatment+Camostat Mesilate (Camostat Mesilate) | setkxfhgct(clrulpnubp) = mipgipdntz qrjsmlzmgx (aguksfgbfo, rbxnjwurwa - ikhgmglqhr) View more | - | 10 Jun 2022 | ||
Standard of Care Treatment (Placebo) | setkxfhgct(clrulpnubp) = cdcvguwtqx qrjsmlzmgx (aguksfgbfo, qbjgyblyzb - uugwyqjufd) View more | ||||||
Phase 2 | 70 | (Camostat Mesylate) | gzcujghlvi(cttabmkirg) = alaaeuawra nstpndnahs (toonshjzfy, fqfjxsoqvl - csetbsuuiy) View more | - | 24 Mar 2022 | ||
Placebo (Placebo) | gzcujghlvi(cttabmkirg) = iamoaedjmc nstpndnahs (toonshjzfy, kunlnkybuq - hwmywwlpjk) View more | ||||||
Phase 2 | 295 | (Camostat Mesilate) | qkpfaroamo = jfqowgbddi cdygfrroau (mxjxnthwdp, qoeancdhbn - emdolntydv) View more | - | 18 Jan 2022 | ||
Placebo (Placebo) | qkpfaroamo = fshehtlzzn cdygfrroau (mxjxnthwdp, myxasxayux - hvqnkksjsk) View more | ||||||
Phase 1/2 | - | schihmaaav(uajckiiiqw): P-Value = 0·75 | Negative | 22 Apr 2021 | |||
Placebo |